Literature DB >> 8977686

Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals.

A Tosti1, B M Piraccini, C Stinchi, S Lorenzi.   

Abstract

Six cases of Scopulariopsis onychomycosis, including four patients with onychomycosis exclusively caused by Scopulariopsis brevicaulis and two patients with a mixed nail infection (S. brevicaulis + Tricophyton rubrum and S. brevicaulis + T. interdigitale), are reported. Four patients presented with a typical distal subungual onychomycosis characterized by subungual hyperkeratosis and onycholysis of the distal nail plate. In two patients, Scopulariopsis infection produced a total dystrophic onychomycosis associated with painful periungual inflammation. Three patients were treated with four pulses of itraconazole, 400 mg daily for 1 week a month, and three patients with terbinafine, 250 mg daily for 4 months. The mycological examination 8 months after discontinuation of treatment showed that one patient was mycologically cured whereas the remaining five patients still carried S. brevicaulis in their nails. The clinical examination at the end of the follow-up period showed a complete cure of the nail abnormalities in only one patient.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977686     DOI: 10.1111/j.1365-2133.1996.tb03895.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  19 in total

Review 1.  Onychomycosis in the elderly.

Authors:  A K Gupta
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzón; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs.

Authors:  Marcelo Sandoval-Denis; Deanna A Sutton; Annette W Fothergill; Josep Cano-Lira; Josepa Gené; C A Decock; G S de Hoog; Josep Guarro
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

4.  In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maria J Buitrago; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

6.  Onychomycosis in Malaysia.

Authors:  K P Ng; T L Saw; M Madasamy; T Soo Hoo
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

7.  Non-dermatophytic molds as agents of onychomycosis in Izmir, Turkey - a prospective study.

Authors:  S Hilmioğlu-Polat; D Y Metin; R Inci; T Dereli; I Kilinç; E Tümbay
Journal:  Mycopathologia       Date:  2005-09       Impact factor: 2.574

Review 8.  Mechanistic Insights of Formulation Approaches for the Treatment of Nail Infection: Conventional and Novel Drug Delivery Approaches.

Authors:  Agrawal Vikas; Patel Rashmin; Patel Mrunali; Rahul B Chavan; Thanki Kaushik
Journal:  AAPS PharmSciTech       Date:  2020-01-14       Impact factor: 3.246

Review 9.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

10.  Interface Scopulariopsis gracilis fungal keratitis following Descemet's stripping automated endothelial keratoplasty (DSAEK) with a contaminated graft.

Authors:  Craig Wilde; Marco Messina; Tara Moshiri; Susan E Snape; Senthil Maharajan
Journal:  Int Ophthalmol       Date:  2017-09-12       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.